Related Experiment Video
Updated: Jul 1, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.2K
Quality Assurance for Stereotactic Body Radiation Therapy for Gynecologic Malignancies
Samuel N Andersen1, Mark D Bonnen1, Michelle S Ludwig2
1Radiation Oncology, University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, USA.
Cureus
|March 4, 2024
Summary
Stereotactic body radiation therapy (SBRT) offers a safe method for dose escalation in gynecologic malignancies for patients ineligible for brachytherapy. Rigorous quality assurance ensures effective treatment delivery and patient safety.
Area of Science:
- Gynecologic Oncology
- Radiation Oncology
- Medical Physics
Background:
- Stereotactic body radiation therapy (SBRT) shows success in other cancer sites but is understudied in gynecologic malignancies.
- Conventional brachytherapy may not be suitable for all patients with gynecologic cancers.
Purpose of the Study:
- To describe a quality assurance (QA) process for delivering SBRT to the pelvis in gynecologic cancer patients.
- To evaluate the feasibility and safety of dose escalation using SBRT for this patient population.
Main Methods:
- Detailed QA protocol including fiducial placement, imaging, immobilization, and treatment verification.
- Patient selection criteria: ineligibility for brachytherapy boost and comprehensive informed consent.
- Dose planning based on brachytherapy literature and physics consultation for optimization.
Main Results:
- Successful implementation of a rigorous QA process for gynecologic SBRT.
- Demonstrated feasibility of delivering high-quality stereotactic dose escalation to the pelvis.
- Physician involvement in survivorship and toxicity management post-treatment.
Conclusions:
- Gynecologic SBRT, when performed with strict QA, offers a safe treatment option for patients ineligible for conventional brachytherapy.
- Preliminary successes warrant further prospective investigation into SBRT for gynecologic malignancies.
